#Breakthrough #SARS-CoV-2 #Infections in the PROVENT #Prevention Trial Were Not Associated with AZD7442 (#Tixagevimab/Cilgavimab) Resistant Variants https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad210/7191107?rss=1
#breakthrough #sars #infections #prevention #tixagevimab
#IDMastodon @Nature #Clinicalimmunology Efficacy of #Tixagevimab and #cilgavimab Against #SarsCoV2 Infections in Patients with #inbornerrorsofimmunity
📌 https://link.springer.com/article/10.1007/s10875-023-01457-z
📌 https://www.springer.com/journal/10875
#IDMastodon #clinicalimmunology #tixagevimab #cilgavimab #SarsCoV2 #inbornerrorsofimmunity
#Genotypic and Predicted #Phenotypic #Analysis of #SARS-COV-2 #Omicron #Subvariants in Immunocompromised Patients with #COVID19 Following #Tixagevimab-Cilgavimab Prophylaxis https://www.sciencedirect.com/science/article/pii/S1386653223000057?dgcid=rss_sd_all
#genotypic #phenotypic #analysis #sars #omicron #subvariants #COVID19 #tixagevimab
#Safety, Tolerability and Pharmacokinetics of Half-Life Extended #SARS-CoV-2 Neutralizing Monoclonal #Antibodies #AZD7442 (#Tixagevimab / #Cilgavimab) in Healthy Adults https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad014/6997870?rss=1
#safety #sars #antibodies #azd7442 #tixagevimab #cilgavimab